Company / Cash per Share
Sarepta Therapeutics Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$8.27
FY2025
5-year range
$4.87 / $26.66
FY2021-FY2025
Trend
-29.7%
vs FY2024
Sector context
#25 of 205
Health Care
What the data says
Sarepta Therapeutics's cash per share of $8.27 is higher than 88% of companies in the Health Care sector (FY2025). Cash per Share has fluctuated over the past 10 years, ranging from $2.68 in FY2016 to $26.66 in FY2021.
Based on SEC 10-K filings.
8.27 in FY2025 with a 5-year CAGR of -5.7%. Top quartile in the Health Care sector.
Improved from $4.87 to $8.27 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -30.2%
- 5-Year CAGR
- -5.7%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 205This company $8.27 Sector average $72.93
▼
-88.7% below sector average
Key checks
Key Insights
- In FY2025, cash per share decreased 29.7% year-over-year.
- Ranks #25 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2021.
- Lowest cash per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.27 | -29.7% |
| FY2024 | $11.77 | +141.6% |
| FY2023 | $4.87 | -79.9% |
| FY2022 | $24.28 | -8.9% |
| FY2021 | $26.66 | +140.0% |
| FY2020 | $11.11 | +112.9% |
| FY2019 | $5.22 | -8.8% |
| FY2018 | $5.72 | -47.7% |
| FY2017 | $10.95 | +308.2% |
| FY2016 | $2.68 | +41.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026